spacer
home > ebr > autumn 2017 > a fresh look
PUBLICATIONS
European Biopharmaceutical Review

A Fresh Look

The European Patent Office (EPO) has recently issued guidance to examiners, indicating that the standard disclaimer used in patent applications to confirm that stem cells have been ‘obtained by means that don’t involve the destruction of an embryo’ is no longer required on moral grounds in some circumstances. Specifically, it should not be required if the patent application was filed after 5 June 2003.

While it has not been widely publicised, this subtle shift in position is highly significant and is thought to indicate an acknowledgement by the EPO of the exciting and valuable research work being carried out in this field and its potential to deliver effective stem cell therapies to treat a range of serious medical conditions. Of course, it may also hint at some recognition that practices have moved on and stem cells no longer have to be sourced from embryos.

Legislative Clarification


The change of approach is directly linked to a key date in the evolution of European patent law, when the Court of Justice of the European Union (CJEU) clarified that a parthenote (a cell where division is kick-started by a chemical or electrical method) is not an embryo, thus eliminating the need to source stem cells from an embryo altogether. Until recently, it was only possible to achieve patent protection for inventions involving stem cell research where the patent application was filed after 10 January 2008 with an accompanying disclosure stating that the stem cells had not been obtained from an embryo.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Helen Henderson is a senior associate and patent attorney at intellectual property firm, Withers & Rogers. She specialises in advising pharma manufacturers about how to protect novel drug formulations and dosage forms, and she has a particular interest in biotech patents.

Dr Nicholas Jones is a partner and patent attorney at Withers & Rogers. A member of the company’s life sciences and chemistry group, he advises pharma and biopharmaceutical businesses about how to protect their innovations and enforce their intellectual property rights. He also advises UCL Business PLC, the technology transfer arm of the University of London.

spacer
Helen Henderson
spacer
spacer
spacer
Dr Nicholas Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

EXTERNAL COMMUNICATION, 24 October 2019, Copenhagen, Denmark PRESS RELEASE – FLYPHARMA CONFERENCE EUROPE 2019

For its fifth annual Europe conference, FlyPharma chose Copenhagen as its host city to address the latest supply chain challenges and industry best practices, putting together a global audience of (bio)pharma and logistics professionals. The two-day conference (22-23 October 2019) aimed to discuss the collaboration and growth within Scandinavia, with a special focus on women in pharmaceutical logistics and an exploration of the industry’s digitalisation and innovation.
More info >>

White Papers
 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement